Simsen Personal™ is a highly sensitive and patient-specific method to monitor circulating tumor DNA (ctDNA).
Simsen Personal™ for ultrasensitive ctDNA monitoring
The patient-specific ctDNA detection approach of Simsen Personal™ is used to monitor the unique genetic characteristics of an individual’s tumor. It enables accurate tracking of treatment efficacy, early resistance detection, minimal residual disease (MRD) monitoring, and optimization for follow-up care plans for better patient outcomes.
Want to know more?
Let’s set up a meeting to discuss how Simsen Personal™ can assist you.
What is circulating tumor DNA?
Circulating tumor DNA (ctDNA) refers to small fragments of DNA that come from dead tumor cells and are found in the bloodstream. These DNA fragments circulate within the bloodstream alongside DNA from healthy cells. The ctDNA contains distinct genetic mutations or changes that are unique to the tumor they originated from.
Why use ctDNA in cancer monitoring?
ctDNA, unlike protein-based biomarkers, is a tumor-specific biomarker, indicating (true) remaining disease within the body. With the help of ctDNA, cancer can be detected years earlier, compared to using standard-of-care tools, such as imaging. Moreover, monitoring ctDNA helps understand tumor genetics, track treatment response or disease progress, and detect minimal residual disease (MRD). Analysis of ctDNA offers a non-invasive way to gather crucial information for cancer diagnosis and management.
Personalization is the key to sensitivity
Why does personal matter?
Personalized ctDNA tests are tailored to the individual’s cancer. A sample of the patient’s tumor is used to identify unique mutations. This personalized approach means the test can identify many more mutations or changes that are unique to the tumor with the following benefits:
FDA recommends ctDNA in clinical trials
Limitations of traditional fixed panels
Fixed sequencing panels test for a predetermined set of mutations. If a patient’s tumor has unique or rare mutations not included in the panel, they won’t be detected. This limitation can lead to a lower sensitivity compared to a tumor-informed approach. Especially for rare, less-studied cancers.
Simsen Personal™ offer exceptional sensitivity without unnecessary complexity
By prioritizing sensitivity while optimizing complexity, Simsen Personal™ aligns with the evolving needs of researchers, clinicians, and biopharmaceutical professionals
Flexible process for elevated insights
Simsen Personal™ delivers advanced ctDNA data for insights in clinical studies and trials. The process starts with a tumor biopsy and plasma sample, followed by Simsen Diagnostics designing a personalized assay. This flexible workflow allows testing multiple samples at different time points on the same platform, providing crucial insights over time for improved treatment assessments.